Related Experiment Video
Updated: Oct 11, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Development of non-dopamine active drugs for negative symptoms
Remy Luthringer1, Michael Davidson2
1Minerva Neurosciences a biotech developing CNS drugs, United States of America.
Abstract:
Most individuals affected by schizophrenia manifest negative symptoms. Because negative symptoms have a persistent deleterious effect on the social and vocational performance of the affected individuals, investigators in academia and pharmaceutical industry are making efforts to develop treatments for this condition. To be successful basic science must expand beyond attempts to interfere with the brain dopaminergic activity and clinical science must improve trials methodology.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antipsychotic Drugs: Typical and Atypical Agents
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Drug Therapy
Antianxiety Medications
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis

